PMID- 25452770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 9
IP  - 1
DP  - 2015 Jan
TI  - Significance of human epidermal growth factor receptor 2 expression in colorectal 
      cancer.
PG  - 17-24
AB  - The aim of the present study was to evaluate the protein expression level of 
      human epidermal growth factor receptor 2 (HER-2) using immunohistochemistry 
      (IHC), and assess the association with clinicopathological parameters and the 
      prognosis of patients with colorectal cancer (CRC). In addition, the current 
      study observed the consistency between the levels of HER-2 protein expression 
      determined by IHC and HER-2 gene amplification determined by fluorescence in situ 
      hybridization (FISH) in the CRC samples. Overexpression of HER-2 and gene 
      amplification were examined with semiquantitative standardized IHC in 878 
      formalin-fixed paraffin-embedded CRC samples, while 102 of these cases were 
      analyzed with FISH. A total of 102 cases (11.6%), out of the 878 cases, were 
      determined by IHC to overexpress HER-2. Of these, 25 cases were strongly positive 
      (IHC3+), while 77 cases revealed moderate staining (IHC2+). HER-2 overexpression 
      was more frequent in early-stage cases compared with advanced-stage cases of CRC 
      (P<0.001). However, there was no association observed between HER-2 
      overexpression and clinicopathological parameters. FISH analysis revealed that 
      64% (16/25) of the IHC3+ cases had HER-2 gene amplification. By contrast, only 
      6.5% (5/77) of the IHC2+ cases, and none of the 20 randomly selected IHC0 or 1+ 
      cases, demonstrated HER-2 gene amplification. Furthermore, no associations were 
      observed between HER-2 overexpression or gene amplification with the survival 
      time. Thus, the present study observed that HER-2 overexpression does not 
      correlate with other clinicopathological data or the survival rate, with the 
      exception of clinical stages. However, IHC3+ and 2+ cases should be further 
      analyzed by FISH to assess the status of the HER-2 gene in CRC. Patients with 
      HER-2 gene amplification may constitute as potential candidates for targeted 
      therapy with trastuzumab.
FAU - Tu, Jinhua
AU  - Tu J
AD  - Department of Pathology, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian 361004, P.R. China ; Department of Pathology, Dongfang Hospital, 
      Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
FAU - Yu, Yinghao
AU  - Yu Y
AD  - Department of Pathology, Dongfang Hospital, Fujian Medical University, Fuzhou, 
      Fujian 350025, P.R. China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Pathology, Dongfang Hospital, Fujian Medical University, Fuzhou, 
      Fujian 350025, P.R. China.
FAU - Chen, Shunping
AU  - Chen S
AD  - Department of Pathology, Dongfang Hospital, Fujian Medical University, Fuzhou, 
      Fujian 350025, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20141111
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC4247305
OTO - NOTNLM
OT  - colorectal cancer
OT  - fluorescence in situ hybridization
OT  - herceptin
OT  - human epidermal growth factor receptor 2
OT  - immunohistochemistry
EDAT- 2014/12/03 06:00
MHDA- 2014/12/03 06:01
PMCR- 2014/11/11
CRDT- 2014/12/03 06:00
PHST- 2014/02/09 00:00 [received]
PHST- 2014/06/20 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2014/12/03 06:01 [medline]
PHST- 2014/11/11 00:00 [pmc-release]
AID - etm-09-01-0017 [pii]
AID - 10.3892/etm.2014.2063 [doi]
PST - ppublish
SO  - Exp Ther Med. 2015 Jan;9(1):17-24. doi: 10.3892/etm.2014.2063. Epub 2014 Nov 11.